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Abstract 
Introduction: although depression has been thoroughly studied in chronic psychosis, we 
do not have a full grasp of the role of depression during a first episode of psychosis (FEP).  
Objective: identifying the predisposing factors of depression in FEP and how they relate 
to an early onset, as well as the clinical consequences in terms of outcome, functioning 
and suicide.  
Method: a review of the existing literature on depression in FEP was performed by an 
online search in Uptodate, Medline and Embase databases, in addition to the on-going 
clinical trials included in Clinicaltrial.gov. The articles selected were examined with the 
advice of a doctor specialized in the subject. 
Results: the prevalence of depression during FEP is high. Prodromal and acute 
depression are now emerging as key factors in the development of future depression, 
with post-psychotic depression rarely happening on its own. While demographic factors 
are not associated with depression, the association between depression and other 
factors such as gender, substance use, duration of untreated psychosis, and the severity 
of positive symptoms is contradictory. Some predisposing factors that are significantly 
linked to depression during all stages of the illness are insight and suicide risk. Although 
a worse outcome and functioning are associated with post-psychotic and persistent 
depression, such relationship is not present in prodromal or baseline depression.  
Conclusion: since the prevalence of depression during FEP is high, an early detection 
and management are needed in order to improve patient outcome. However, more 
research into this subject is required to have better knowledge of depression in FEP.  
Key words: First episode psychosis, Depression, Prevalence, Suicide, Outcome 
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Resumen 
Introducción: aunque la depresión se ha estudiado más a fondo en la psicosis crónica, 
el papel de la depresión durante un primer episodio de psicosis (PEP) no se comprende 
completamente. 
Objetivo: identificar los factores predisponentes de la depresión en PEP y cómo se 
relacionan con un inicio temprano, así como las consecuencias clínicas en cuanto a 
resultados, funcionamiento y suicidio. 
Método: se realizó una revisión de la literatura existente sobre la depresión en PEP 
mediante una búsqueda en las bases de datos de Uptodate, Medline y Embase, además 
de los ensayos clínicos en desarrollo incluidos en Clinicaltrial.gov. Los artículos 
seleccionados fueron examinados con el asesoramiento de un médico especializado en 
el tema. 
Resultados: la prevalencia de depresión durante PEP es alta. La depresión en las fases 
prodrómica y aguda está emergiendo como factor clave en el desarrollo de depresión 
en el futuro, mientras que la depresión post-psicótica rara vez ocurre por sí sola. Si bien 
no se han encontrado factores demográficos asociados con la depresión, la asociación 
entre la depresión y otros factores como el género, el uso de sustancias, la duración de 
la psicosis no tratada y la gravedad de los síntomas positivos es contradictoria. Algunos 
factores predisponentes que están significativamente asociados con la depresión 
durante todas las etapas de la enfermedad son la percepción y el riesgo de suicidio. A 
pesar de que un peor resultado y funcionamiento están asociados con la depresión post-
psicótica y persistente, tal relación no está presente en la depresión prodrómica o 
aguda.  
Conclusión: dado que la prevalencia de depresión durante PEP es alta, se necesita una 
detección y manejo tempranos para mejorar el resultado del paciente. Sin embargo, se 
requiere más investigación sobre este tema para tener un mejor conocimiento de la 
depresión en PEP. 
Palabras Clave: Primer episodio de Psicosis, Depresión, Prevalencia, Suicidio, 
Consecuencias 
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1. Introduction 
The term First Episode of Psychosis (FEP) refers to individuals with the initial symptoms 
of a psychotic illness who have not been previously treated, though they might have 
earlier presented prodromal symptoms or subtle premorbid signs. Within the different 
cases of FEP, the most common diagnosis is schizophrenia and the usual age range in 
which the first episode occurs is between 15 and 30 years old (Jones, 2013; McGrath et 
al., 2004).  
In the pathogenesis of FEP, neurodevelopmental abnormalities, brain changes such as 
the decrease of grey matter in multiple brain regions, and epigenetic factors come 
together to bring about the onset of the illness (Pantelis et al., 2003; Weinberger, 1996).  
The clinical manifestations of the illness include psychotic symptoms (hallucinations, 
delusions, thought disorganization, agitation, and aggression), neurocognitive 
impairment (memory, attention, processing speed and executive function), metabolic 
abnormalities, functional impairment and suicide (J. Addington et al., 2012; Hor & 
Taylor, 2010; Spelman, Walsh, Sharifi, Collins, & Thakore, 2007). Another possible form 
of presentation of FEP is the manifestation of depressive symptoms such as anhedonia, 
dysphoria, amotivation, which is usually associated with a poorer outcome of the illness 
(Brunett et al., 2009). 
Symptoms of depression have consistently been reported frequent in patients with 
schizophrenia (Cotton et al., 2011; Oosthuizen et al., 2002). Due to the differences 
between studies, lifetime prevalence results range from 6 to 75 percent, with an 
estimated modal prevalence of 25 percent (S. G. Siris, 2000). Compared to the 12 
percent estimated lifetime prevalence of unipolar major depression and persistent 
depressive disorder in adults (Hausmann & Fleischhacker, 2002), depression in psychosis 
entails a high prevalence rate.  
As defined by the ICD 10 (World Health Organization, n.d.), post schizophrenia 
depression consists on a depressive episode which occurs within the illness outcomes, 
with positive or, usually, negative symptoms being present, though not dominant. 
Whether the depression is reactive or intrinsic to the illness or has been uncovered after 
symptom resolution is irrelevant when establishing a diagnosis. Therefore, post 
psychotic depression would be diagnosed if the patient meets schizophrenia criteria in 
the last 12 months, some symptoms are still present, depressive symptoms meet the 
criteria for a depressive episode, and the episode has lasted 2 weeks minimum.  
For a long time, post psychotic depression or depression between episodes have been 
the focal points of studies about depression in psychosis. However, this definition about 
depression in psychosis does not include symptoms during a first episode of psychosis 
or at a prodromal phase and the impact of this is yet to be fully understood. This could 
be partly explained by the sometimes-present difficulties when diagnosing depression 
in psychosis, since depressive symptoms can be misinterpreted as side effects, negative 
symptoms, or other disorders.  
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Nowadays, studies focusing on FEP have used different scales in order to identify 
depression at this stage of the illness. Some studies (Bornheimer, 2018; Brunett et al., 
2009; Lopez-Morinigo et al., 2018; Lyngstad et al., 2018; Romm et al., 2010; Upthegrove, 
Ross, Brunet, McCollum, & Jones, 2014) use the Calgary Depression Scale for 
Schizophrenia (CDSS) to differentiate between patients with and without depression 
during the acute phase or at follow-up (Appendix I). This interview separates depression 
from negative and extrapyramidal symptoms and the cut-off point is stablished at 7, 
with a higher score predicting moderate to severe depression(Addington, Donald; 
Addington, Jean; Maticka-Tyndale, 1993). To determine if depression was present in the 
prodromal phase, that is, a depressive episode in the previous 6 months prior to onset, 
the tool used was the Schedule for Clinical Assessment in Neuropsychiatry (SCAN) 
(Brunett et al., 2009; Upthegrove et al., 2014). Others (R. J. Drake et al., 2004; Gardsjord 
et al., 2018; Lopez-Morinigo et al., 2018; Oosthuizen et al., 2002; Simonsen et al., 2018), 
used the depression item (G6) on the Positive and Negative Symptom Scale for 
Schizophrenia (PANSS) or (Cotton et al., 2011) the depression score of the Clinical Global 
Impressions-Severity of the Illness Scales-Bipolar Illness (CGI-BP) or the item on the 
Hamilton Depression Rating Scale (HAMD-17) (Dai et al., 2018; Koreen AR, 1993).  
The aftermath of depression in schizophrenia can be daunting, considering it has been 
associated with a higher suicide risk, poor response to treatment, increased number and 
duration of hospitalization, cognitive and social disability, in addition to adverse life 
events (Buckley, Miller, Lehrer, & Castle, 2009; Conley, Ascher-Svanum, Zhu, Faries, & 
Kinon, 2007).  
It is a known fact that psychiatric disorders are strong predictors of suicide, where the 
severity of the illness is related to the risk, and psychotic illnesses could not be less. Early 
stages such as the first episode of psychosis constitutes a very high-risk period of suicide. 
(Brunett et al., 2009; Tidemalm, Långström, Lichtenstein, & Runeson, 2008). When 
studying the suicide risk in patients with depression alone, there is a correlation 
between previous history and feelings of worthlessness, as well as concurrent 
personality disorder (Haukka, Suominen, Partonen, & Lönnqvist, 2008).  
The aim of this review is to determine if there is a high prevalence of depression in 
patients with a first episode of psychosis (FEP), the possible predisposing factors and 
how this could affect the course of the illness in terms of suicide risk, cognitive outcome, 
answer to treatment and quality of life.  
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2. Methods 
In order to review the current literature on depression in a first episode of psychosis and 
its predisposing factors, an online search was carried out on UpToDate information, 
scientific journals from the Medline database, via Pubmed and Embase, as well as the 
clinical trials included in the Clinicaltrials.gov site. The search terms “First Episode 
Psychosis”, “depression”, “incidence”, “prevalence”, “First Episode Schizophrenia” and 
“suicide” were used.  
The full articles were read by the author in pursuance of selecting those suitable for our 
review. The studies focusing on chronic schizophrenia were initially ruled out, choosing 
the ones concerning a first episode of psychosis with emphasis on their depression 
measurement relevance. The selected articles were later examined with the advice of a 
doctor specialized in the subject. Given the limited research on depression in FEP, the 
review was completed with information extracted from previous research about 
depression in schizophrenia, as a means to set a knowledge base for the research, 
without obscuring our results regarding FEP.  
Within the 29 clinical trials about First Episode Psychosis found, the 8 trials that included 
both the study of a first episode and measurements of depression were chosen, in 
addition to the ones focusing only on treatment. 
Finally, with the aims of expanding the existing knowledge on the subject and answering 
the hypotheses raised on the relationship between depression and FEP, all the 
information extracted was reviewed.  
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3. Results 
Within the scope of knowledge, depression is common during early phases of psychosis 
(Cotton et al., 2011; Koreen AR, 1993; Oosthuizen et al., 2002; Romm et al., 2010; S. G. 
Siris, 2000), whether it is in the prodromal, acute, or post psychotic phase. Similarly to 
depression in long-term schizophrenia, the prevalence rate of depression in FEP varies 
between studies, ranging from 17% to 83% (D. Addington, Addington, & Patten, 1998; 
Koreen AR, 1993; Romm et al., 2010). A few examples of this are the study by (Romm et 
al., 2010) who found a 48% rate of depression in patients with FEP and (Brunett et al., 
2009) who detected an 80 % incidence rate of depression (table 1), occurring in either 
one or multiple phases, with prodromal depression playing a pivotal role in future 
events.  
 
Previous studies about depression in psychosis were focused on the emergence of 
symptoms after the acute episode was resolved, since it was considered the time in 
which depression occurred. However, this was due to the less-noticeable nature of 
depressive symptoms, being camouflaged when they happened during an acute episode 
and disappearing as the episode remitted. As a matter of fact, (Cotton et al., 2011) found 
a co-morbid clinical diagnosis of major depression disorder in only 29.2% of FEP patients 
studied with depressive symptoms.  
Prodromal depression 
 
Depressive symptoms such as altered energy levels, feelings of hopelessness, loss of 
interest, social isolation, concentration, appetite and sleep disturbances, are common 
during the prodromal phase of psychosis, being present in 28 to 76% of patients.  This 
can last days or weeks with psychotic symptoms increasing until becoming predominant. 
In the study by (Brunett et al., 2009) the incidence rate of depression during this phase 
was 51%, while (Romm et al., 2010) reported an 17% rate in a smaller cohort.  
Study Number of 
participants 
Depressive 
symptoms 
measure 
Depression prevalence rate 
Prodromal 
depresion 
Baseline 
depression 
Postpsychotic 
depression 
Koreen 1993 70 HAMD-17  75% 26% 
Lyngstad 2018 125 CDSS  33% 25.4% 
Cotton 2012 405 CGI-BP  26.2% 14.2% 
Upthegrove2009 136 SCAN/CDSS 51% 59% 39% 
Bornheimer 2018 404 CDSS  12.46%  
Oosthuizen 2002 80 PANSS  56%  
Upthegrove2014 92 SCAN/CDSS 56% 59% 27% 
Romm2010 122 CDSS 17% 30% 22% 
Dai2017 240 HAMD-17  54.6%  
 
Table 1: Prevalence rates of depression at different illness stage. Abbreviations: HAMD-17, Hamilton Depression 
Rating Scale; CDSS, Calgary Depression Scale for Schizophrenia; CGI-BP, Clinical Global Impression Scale for Bipolar 
Disorder; SCAN, Schedule for clinical assessment in Psychiatry; PANSS, Positive and Negative Syndrome Scale. 
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As mentioned before, it has been suggested that prodromal depression is an essential 
factor for developing depression later in the course of the psychotic illness. Symptoms 
of depression were, in fact, more severe if the patient had suffered from depression 
during the prodromal phase (Brunett et al., 2009). 
Acute depression 
 
Nonetheless, prodromal depression was not the only factor when considering the 
development of future depression. Upthegrove et al. (2009) found that the presence of 
depression during the acute phase was significantly correlated to a more severe, harsher 
depression at follow-up, disagreeing with previous studies who failed to find an 
association between prodromal and post-psychotic depression, along with outcome and 
relapse (Koreen AR, 1993). In this study, the CDSS depression score at baseline was 
significantly lower in affective psychosis compared to those with non-affective psychosis 
(Brunett et al., 2009).  
Therefore, they found that both prodromal and acute depression were predictors of 
future depression. This goes against previous beliefs of a depression prediction based 
on the extent of the positive or negative symptoms or the categorization of the illness 
as affective. In many cases, depression is manifested before the emergence of other 
symptoms, thus supporting the hypothesis of depression as a part of the illness and not 
as a consequence, as previously believed (Brunett et al., 2009; Oosthuizen et al., 2002).  
Post-psychotic depression 
 
With all this, depression has now been acknowledged as a main trademark of the acute 
episode of psychosis and happens uncommonly after a first episode is resolved (Brunett 
et al., 2009; Koreen AR, 1993). A higher rate of depression has been found when focusing 
on depression that occurs after the acute phase of FEP or near, compared to the one 
present when the illness is settled, being associated with different psychological 
phenomena (R. J. Drake et al., 2004; Upthegrove et al., 2014).  
In order to understand the different mechanisms that lead to post psychotic depression, 
psychological models have been suggested, such as the one from Birchwood et al. in 
which the emergence of depression is related to an increased insight as well as the 
illness perception (Birchwood, M., Iqbal, Z. & Upthegrove, 2005). These models 
suggested that the resolution or improvement of psychotic symptoms would lead to 
greater insight, lowering the patient’s self-esteem, and predisposing them to the 
development of depression (R. J. Drake et al., 2004).  
In the study by Upthegrove et al. (2014), post psychotic depression was defined as a 
follow-up depressive episode with a Calgary Depression Scale for Schizophrenia higher 
than 7. A bigger sense of loss, shame, and less control were indeed related to 
depression, implying a higher risk, as well as low level continuing positive symptoms and 
a greater need for treatment. Contrary to what was initially assumed and in favour of 
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ICD-10’s diagnosis of post-psychotic depression, insight in this study was not higher in 
patients with PPD.  
When prodromal or acute depression are not present, the so-called post psychotic 
depression is uncommon to appear. Although the incidence of depression during a later 
stage of the illness might be high, this is related to the presence of previous symptoms 
of depression in a patient (Brunett et al., 2009). 
3.1. Predisposing factors 
 
One could think that the presence of depressive symptoms could be influenced by 
demographic factors such as education, ethnicity, or age, though previous studies 
(Oosthuizen et al., 2002; Romm et al., 2010; Upthegrove et al., 2014) found no 
significant differences in patients with and without depression in FEP.  
Given the tendency of mood disorders to occur in female patients, a question arises as 
to whether the symptoms of depression in FEP are more frequent in women. Oosthuizen 
et al. (2002) found that depressive symptoms at baseline were slightly higher in women, 
while Romm et al. (2010) noticed an association between depressive symptoms and 
alcohol use in men, and excitative symptoms as well as duration of untreated psychosis 
(DUP) in women. In this study, 30% of women had one or more major depressive 
episodes (MDE) in comparison with 10-15% of men. However, in the study by Dai et al. 
(2018), depressive symptoms were slightly lower in women (48.1%) than men (62.2%). 
Finally, Upthegrove et al. (2014) found no gender differences between patients with 
depression and those without it.  
Multiple factors could be responsible for the presence of depressive symptoms in FEP, 
including a subjective reaction to the illness, accompanying adverse life events, 
substance abuse, co-morbid major depressive disorder, anxiety disorders, or neuroleptic 
induced dysphoria (Oosthuizen et al., 2002). These factors could act as stressors 
initiating the depression or even depressive symptoms themselves could be the ones 
decompensating vulnerable individuals and triggering psychosis, as explained by the 
stress-diathesis model. Based on this model, patient vulnerability would not only be 
defined by specific predisposing factors, but constitute a continuum varying from high 
vulnerability patients waiting for psychosis to happen to the very low risk majority of 
people, passing through a group of population for whom stressors would be the 
determining factors when establishing the development of the disorder (S. G. Siris, 
2000).  
Premorbid adjustment with characteristics of indecisiveness and rumination might be of 
importance when identifying those who could benefit from a prompt assessment.  
Romm et al. (2010) found an association between poorer premorbid childhood social 
and academic functioning and level of depression at start of treatment. These 
individuals would therefore be vulnerable to depression, which could serve as an 
identifier of possible future psychosis and an early intervention target (Brunett et al., 
2009). However, this vulnerability could be just a small part of a bigger picture, with 
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neurobiological and cognitive factors coming together to form the physiopathology of 
depression in FEP (Brunett et al., 2009).  
Perhaps underlying a common psychopathology behind them or a susceptibility in these 
patients, depressive symptoms were found related to family history of psychiatric 
disorders, past history of major depressive disorder, suicide attempts, and higher insight 
(Cotton et al., 2011). 
Substance use  
 
Compared to the general population, there is a high rate (up to 50%) of substance use 
disorders including cannabis, stimulants, and opioids, in patients with FEP (Brunette et 
al., 2018). These consumptions and specifically the use of cannabis constitutes a risk 
factor for the development of psychosis (Moore et al., 2007). However, recent studies 
show no association between depression during the acute phase and the use of 
substances (Brunett et al., 2009), which were actually less consumed by depressed 
patients. Furthermore, depressed patients were less likely to be hospitalized, 
contradicting previous data and not explained by psychopathology differences (Cotton 
et al., 2011). 
Duration of untreated psychosis and symptomatology 
 
The duration of untreated psychosis (DUP) is another controversial predisposing factor 
of depression. While some studies found an association between a longer DUP and the 
severity of depressive symptoms in women (Romm et al., 2010) and suicidal ideation 
(Bornheimer, 2018), others failed to find this relationship (Oosthuizen et al., 2002). 
Whereas Brunett et al. (2009) and Upthegrove et al. (2014) only found DUP related to 
depression when talking about a later phase of the illness.  
In this line of thought, Brunett et al. (2009) described that depression severity was not 
correlated with psychotic symptomatology, as a higher rate of either positive or negative 
symptoms did not imply a more severe depression, contrary to the results obtained by 
Koreen AR (1993), who found an association between depression and a greater severity 
of psychotic symptoms. PANSS scale score was not higher in patients with depression, a 
disparate finding with that obtained in the study by Dai et al. (2018), who found a higher 
PANSS score in those with depressive symptoms. Contrary to its relevance in post 
psychotic depression and suicidal ideation, the severity of positive symptoms, along with 
the duration of untreated psychosis, is not a strong predictor of acute depression 
(Bornheimer, 2018; Upthegrove et al., 2014).  
However, in the study by Oosthuizen et al. (2002), baseline depression was associated 
with negative symptoms, though only explaining a small portion of them, while later 
depression was associated with both positive and negative symptoms. Therefore, 
depressed patients have a milder course in terms of negative symptoms. Positive 
symptoms, on the other hand, were not linked to depression scores, which reinforces 
the hypothesis of both phenomena appearing independently. 
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Insight 
 
Another important factor we should consider when talking about depression in FEP is 
insight. Although the existing evidence of the relationship between insight and 
depression is divergent, this review aims to shed some light on how they affect one 
another.   
Along with factors such as family history of depression, lack of social support, multiple 
hospitalizations, or recent hospital discharge, insight has been considered one of the 
main risk factors of depression in schizophrenia.  
In order to evaluate insight in psychosis, multiple approaches can be taken. One of them 
is the proven reliable Insight Scale (IS), which consists of eight questions that measure 
awareness of illness, symptoms and need for treatment. When the result of this scale is 
high, this implies a greater insight (Birchwood et al., 1994). Another essentially similar 
measuring scale is the Schedule for Assessment of Insight scale-expanded version (SAI-
E), which follows this multidimensional model of insight (Lopez-Morinigo et al., 2018). 
Another way of assessing insight by some studies is the insight item on the PANSS scale.  
As previously explained, it was assumed that the resolution of psychotic symptoms 
would lead to an increased insight with a better understanding of the illness and the 
predisposition for the development of depression, though this was later rejected (R. J. 
Drake et al., 2004).  
In the study by Drake et al. (2004), insight was not related to paranoia, since 
confounders were present in the relation between greater symptom severity and lower 
insight. As they hypothesised, insight was associated with depression, with better insight 
predicting greater depression in psychosis, especially in acute stages of the illness. In 
support of this, Cotton et al. (2011), found that patients with greater depression were 
the ones with greater insight not only at entry, but at discharge  This correlation 
between depression and insight was also found on the study by Morinigo et al. (2018). 
However, Gardsjord et al. (2018), found that better insight was linked to higher 
depression at baseline as well, though not at follow-up. This might be because the 
association is in part moderated by the severity of the illness, as recent studies have 
explained (Belvederi Murri M, Amore M, Calcagno P, Respino M, Marozzi V, 2016). 
Moreover, in the study by Upthegrove et al.(2014), insight throughout the illness was 
not linked to depression. Although moderate insight was found in the number of 
patients studied, there were no differences in the score obtained by depressed and non-
depressed patients. When breaking down the different components of the evaluation 
of insight, awareness of the illness and negative appraisals were higher in patients with 
depression in the acute phase, as well as feelings of loss, shame and entrapment. In fact, 
in the study by drake et al. (2004), both insight and depression were weakly related to 
low self-esteem, though their relation was not specified, and other factors were 
involved. 
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In spite of not being related to insight, paranoia was in fact associated with depression, 
as a probable cause and a strong predictor at follow-up. Although these factors were 
clearly related, these associations were milder as the time passed, suggesting an 
adjustment process. Since paranoia was not related to insight, there would be no place 
for treating paranoia in order to achieve greater insight, though there might be a 
beneficial impact on insight not dependent of paranoia. Nonetheless, treatment of 
positive symptoms can be the key to treating depression, specially at the acute phase 
when it is most important (R. J. Drake et al., 2004).  
Despite the relation between insight and depression, insight has been found relevant in 
psychosis, predicting better outcomes.  
Finally, insight has also been related to suicide risk in first-episode-psychosis (Cotton et 
al., 2011), though when studied further, confounders such as depression and previous 
suicide history were identified as the main factors increasing the association perceived. 
This revealed the influence previous self-harm history had on insight levels at onset 
(Lopez-Morinigo et al., 2018). 
3.2. Clinical consequences of depression in FEP 
 
With these results, the model of depression in FEP suggested by Upthegrove et al. (2014)  
consists on a base of susceptibility and environmental factors resulting in depression in 
the prodrome, which increases, combined with illness appraisals and voice and threat 
perception, future risk of depression.    
In the study by Upthegrove et al. (2014), depression in the acute first episode of 
psychosis was associated with higher engagement and malevolence and lower 
benevolence scores when evaluated by the Beliefs about Voices Questionnaire (BAVQ-
R), which measures different characteristics from the patient’s auditory hallucinations. 
Moreover, the Details of Threat Questionnaire (DOT) scores were higher in depressed 
patients with stronger persecutors and a bigger affliction caused by menaces with an 
inability to manage them. Based on this, it was proposed that some of the patients who 
experience depression do it as a result of the personal experience of the symptoms, 
though this was slightly statistically significant. 
Moreover, there were higher Safety Behaviour Questionnaire (SBQ) scores and negative 
illness appraisals as measured by the Personal Beliefs about Illness Questionnaire (PBIQ-
R). Although it has been indicated that prodromal depression is an important predictor 
of depression, when controlled, other predictors emerge, such as negative illness 
appraisals. These, in contrast to positive symptoms, are not resolved as the episode 
settles, which contributes to the previously mentioned hypothesis of causality between 
depression and illness perception (Upthegrove et al., 2014). 
Outcome 
 
Depression in FEP is associated to a poorer outcome and relapse (Upthegrove et al., 
2014). However, this might be stage dependant, with higher baseline depression scores 
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being a favourable prognostic indicator and predicting fewer negative symptoms later 
on, and persistent symptoms of depression or their later emergence predicting a poorer 
outcome (Oosthuizen et al., 2002). Other research supports this idea such as the study 
by Gjardsgord et al. (2018), who studied Subject Quality of Life (S-QoL) as an outcome 
measure by the Lehmen’s Quality of Life Interview and its association with depression 
and functioning. Both factors showed a significant negative effect on S-QoL, with higher 
depressive symptoms resulting in a lower quality of life. However, this was only during 
the follow-up period, with baseline symptoms showing no such association. In view of 
this, it could be presumed that there is a different pathological base for depression at 
different illness stages.  
Apart from the known correlation between negative symptoms and a poor outcome, in 
the study by Oosthuizen et al. (2002), no association between baseline depressive 
symptoms and outcome was found. Therefore, a higher baseline depression did not 
equal a worse outcome, but it implied a favourable prognostic indicator. 
Different outcome measures were also analysed by Simonsen et al. (2018), who studied 
self-rated disability as measured by the Assessment Schedule 2.0. They found that self-
rated disability was closely related to life satisfaction and depressive symptoms, as 
previously reported by Chudleigh et al. (2011), who also found an association with social 
anxiety. Although the direction between depression and self-rated disability was not 
clarified when evaluated at 1-year follow-up, they found baseline levels of depression 
to be a predictor of self-rated disability, especially in two social domains: “getting along 
with people” and “participation in society”. Moreover, they concluded that self-rated 
disability was an outcome measure on its own, distinctive from functioning and life 
satisfaction, thus needing its appropriate assessment (Simonsen et al., 2018).  
Functioning 
 
Some research has failed to find significant association between depression and 
functioning. However, the study by Lyngstad et al. (2018) found a significant association, 
positive symptoms and apathy aside, between depression and the Global Assessment of 
Functioning Scale-Split version, functioning subscale (GAF-F) scores. This association 
between depression and poor functioning was especially relevant in patients with 
persistent depression, determined as having a CDSS score of 7 or higher both at baseline 
and at one-year follow-up.  
Although the depression rate was higher during the acute phase, this did not translate 
into altered functioning at this phase. The prevalence of depression was higher when 
associated with persistent apathy, categorized as an Apathy Evaluation Scale (AES-C) 
score of 27 or higher at both baseline and follow up, which was found to have a higher 
prevalence. Associations between depression, apathy and poor functioning were 
especially noticeable with persistent symptoms, compared to those patients 
experiencing fluctuating symptoms, whose functioning difficulties were milder. Though 
initially considered additive, the impact produced by persistent depression and apathy 
was independent, underlying the different neurobiological mechanisms responsible, 
apart from the reduced motivation (Lyngstad et al., 2018).  
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Persistent depression has been linked to poor follow-up functioning by other studies 
such as Cotton et al. (2011), who found an association between persistent depression 
together with past history of a major depressive disorder and a poor outcome when 
evaluated at 18 months, as well as in the long term of 5-10 years in the study by Sönmez 
et al. (2016).  
Suicide 
 
Suicide risk is another important factor that comes in to play when it comes to the 
evolution of the illness. Psychotic illnesses have a high risk of suicide, being specifically 
higher around the time of the first episode and usually heralded by feelings of 
depression and hopelessness, which act as essential predictors (Brunett et al., 2009; 
Thorup et al., 2002).  
This association between suicidal thinking, behaviour, and hopelessness has been 
recently studied in the meta-analysis carried out by Ribeiro et al (2018), where they 
found an association between hopelessness and an increased risk of ideation, attempted 
and consummated suicide. 
In order to achieve suicide or self-harm, overdose was the main method used by studied 
patients. Other means such as hanging, cutting, walking in front of traffic, or jumping 
from a height were not presented in as a big of a magnitude, although they were not 
trivial (Brunett et al., 2009). 
Acts of self-harm and suicidal thinking have been related to depression in FEP, being 
present not only during the early phases of the illness, but as it progresses. The studies 
by Bornheimer et al. (2018) and Melle et al. (2006), have found the prevalence rate of 
suicide to be highest in the first year after starting treatment; whereas others (Brunett 
et al., 2009) found that the majority of acts of self-harm happened during a phase in 
which the illness was not being treated. This might have been a result of the phase of 
the illness in which these studies have been performed, with the latter focusing on First 
Episode Psychosis.  
This high risk period could be associated with greater insight, depressive symptoms 
(Cotton et al., 2011), as well as the duration of untreated psychosis (DUP), which has 
been consistently reported to be higher in patients with suicidal ideation (Bornheimer, 
2018).  
A better insight into the illness has been related to a higher risk of suicide in various 
meta-analysis (Challis, Nielssen, Harris, & Large, 2013; Hawton, Sutton, Haw, Sinclair, & 
Deeks, 2005). Although it was initially thought that insight preceded depression, which 
resulted in a higher suicide risk (R. E. Drake & Cotton, 1986), recent research into the 
matter has revealed that this relationship could even be beneficial (Barrett et al., 2015). 
The magnitude in which suicide risk is affected by insight could have been 
misinterpreted due to the confounding role of previous self-harm history and 
depression. This was brought to light by the recent study carried out by Lopez-Morinigo 
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(2018), where they found that previous suicide history before onset had an impact on 
insight.  
Going back to our subject of study, there is a higher rate of depression at baseline in 
patients who report suicidal thoughts (Bornheimer, 2018; Cotton et al., 2011), being 
found together in up to 63% of patients (Brunett et al., 2009). In fact, some studies have 
reported an equidistant growth between suicidality and symptoms of depression, with 
a more severe depression resulting in a higher risk of suicide attempts (Gonzalez-Pinto 
A, Aldama A, Gonzalez C, Mosquera F, Arrasate M, 2007). Furthermore, previous acts of 
self-harm history have been significantly related to persistent depression (Cotton et al., 
2011; Sönmez et al., 2016). 
Although there was a decrease on the number of acts of self-harm attempted by 
participants of some studies at follow-up, there was an association between depression 
and acts of self-harm after the resolution of the first episode. When studying all the 
demographic factors and patient’s characteristics, including gender, prodromal 
depression was the only predictive factor of importance (Brunett et al., 2009). 
Suicide risk is therefore influenced by many factors, so our aim should be to investigate 
those we do not know and asses those we can identify. There is no doubt that if the 
presentation of suicide thinking is during the acute phase, these patients would need 
specific treatment for it. However, we should consider future risk, perhaps predicted by 
self-harm history, in order to reduce suicide rates and establish a better outcome for 
these patients, even in those without depression or suicide thoughts at baseline 
(Bornheimer, 2018). There could also be a higher risk of patients with an early onset of 
the illness, which could be lessened, as mentioned above, with an early intervention, 
although this is yet to be confirmed (Brunett et al., 2009; Lopez-Morinigo et al., 2018).  
Since pharmacotherapy on its own, such as atypical antipsychotics, has not shown risk 
reduction, maybe we should be focusing on secondary prevention. This early 
intervention would consist on detecting and treating depression, hopelessness and 
psychosis at their earliest stages possible, especially in those considered more 
susceptible (Brunett et al., 2009). Another mainstay in this treatment could be cognitive 
therapies with family and patient psychoeducation, suicide risk evaluation, means of 
suicide reduction, control, and support of important life experiences (Bornheimer, 
2018). In this line of treatment, there are programs such as Cognitive-Behavioural 
Suicide Prevention for Psychosis and skills training programs (Tarrier et al., 2013). 
Improving insight, however, should not be a main treatment goal, since its magnitude 
has been shown not to be related to future risk (Lopez-Morinigo et al., 2018). 
Given the relationship between depression and suicide, it is safe to say patients would 
benefit from antidepressant medication. However, there is no established protocol as 
to the management of a first episode. With an early treatment, patients would benefit 
from suicide risk reduction as well as improving their functional outcomes. In order to 
achieve this, more in-depth knowledge about this matter would be beneficial 
(Upthegrove et al., 2014).  
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4. Discussion 
For years, depressive symptoms have been recognized present in schizophrenia. 
However, it was not until recently that this relationship started to be studied in first 
episode of psychosis, with the latter being a new concept.  
After reviewing the literature and answering our 
review aims, we can conclude that depression is 
frequent in patients with their first episode of 
psychosis. Whether it is a consequence of the scales 
used on its measurement and the variable 
prevalence of depression according to the stage of 
the illness or not, the range of depression 
prevalence obtained is very wide: 12.5-75% (Figure 
1). Therefore, a consensus on establishing an all-
around measurement criterion should be 
achieved in order to reach a definite, yet more 
representative, prevalence rate. 
Unlike the preconceived idea that depressive symptoms can be confused with side 
effects, negative symptoms or other disorders during an acute phase of FEP where 
psychotic symptoms stand out, we have seen that we have enough tools to be able to 
identify signs of depression in these patients, thanks to the use of scales such as the 
CDSS (Addington, Donald; Addington, Jean; Maticka-Tyndale, 1993). We should 
therefore strongly consider the hypothesis of depression as a part of the illness and be 
aware of the importance on its assessment (Oosthuizen et al., 2002). 
Apart from post psychotic depression, which has been studied more thoroughly, other 
important components of depression in FEP are now arising, revealing that depression 
can not only coincide, but precede psychosis (Romm et al., 2010). On that note, 
prodromal depression emerges as a main component of depression in FEP, as well as a 
predictor of future depression, along with the crucial role played by acute depression 
(Brunett et al., 2009).  
Therefore, post-psychotic depression, initially considered as one of the key clinical 
elements in the study of FEP, and being in association with a greater insight, feelings of 
loss, shame, and low self-esteem (R. J. Drake et al., 2004), is now losing importance, 
being conceived as a consequence of these previous symptoms that act as predictors 
and only occasionally occurring on its own (Upthegrove et al., 2014) 
The prevalence of depression varies not only with population, which could be in line 
with a genetic susceptibility, but also with group studies within the same population, 
which correlates with the evidence of no demographic association between depression 
and FEP (Dai et al., 2018). The information regarding gender relevance on depression in 
FEP is contradictory, since depressive symptoms have been found to be more severe in 
women in some studies (Romm et al., 2010), while others found a lower incidence in 
women (Dai et al., 2018), or found no differences whatsoever between genders 
(Upthegrove et al., 2014).  
Figure 1: Baseline depression prevalences.  
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Taking into account the difficulties on measuring susceptibility (Lyngstad et al., 2018), 
some studies concur on the existence of patient’s characteristics that make them more 
prone to develop depression in psychosis, such as indecisiveness, rumination, and a 
poorer premorbid childhood social and academic functioning (Romm et al., 2010).  
Along with these characteristics, we find the knowledge about substance use as a 
predisposing factor of depression in these patients to be inconsistent. Another 
incongruous predictor of depression is the duration of untreated psychosis, though most 
of the literature seems to find it only associated with post-psychotic depression, just like 
the severity of positive symptoms (Bornheimer, 2018; Brunett et al., 2009; Upthegrove 
et al., 2014).  
On the other hand, insight has been unequivocally proven to be significantly associated 
with depression during all stages of the illness (Cotton et al., 2011; R. J. Drake et al., 
2004; Lopez-Morinigo et al., 2018). This relevance was mostly derived from the 
awareness of the illness, as well as feelings of loss, shame, and entrapment (Upthegrove 
et al., 2014). Paranoia was also found to be linked to depression, though of no 
importance in the relationship between insight and depression. What was in fact related 
to insight was the previous history of self-harm (Lopez-Morinigo et al., 2018).  
More research into the matter is needed in order to identify the predisposing factors 
and shed some light into all these contradictions. The best way to achieve this might be 
carrying out clinical trials in patients with FEP (Appendix II). The observation and study 
of patients with first episode of psychosis offers great advantages when it comes to 
understanding the characteristics of the disease and its own psychopathology, without 
the interference of confounding factors such as the duration of the disease itself and the 
comorbidities that appear during its evolution, as well as the effects derived from 
treatment (Dai et al., 2018).  
Understanding all these predisposing factors and the manifestation of depressive 
symptoms during the first episode have much to say regarding the extent of the disease. 
Depression in FEP was associated to worse perception of voices, stronger persecutors 
and distress caused by threats, together with negative illness appraisals (Upthegrove et 
al., 2014).  
Although an unfavourable outcome has been related to depression in psychosis, it 
seems that baseline depression does not follow this idea. In fact, acute depression might 
represent a good prognostic indicator with lower negative symptoms in the future, while 
post-psychotic depression and negative symptoms are the ones responsible for a worse 
outcome, implying a lower quality of life (Gardsjord et al., 2018; Oosthuizen et al., 2002). 
However, one outcome domain has been associated with baseline depression, that is, 
self-rated disability, finding an impact on two measurements: “getting along with 
people” and “participation in society” (Simonsen et al., 2018).  
Functioning is another clinical consequence that has been associated with depression, 
specifically post-psychotic. Even though depressive symptoms were higher in the acute 
stage, the relation between functioning and depression was only relevant in patients 
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with persistent symptoms. Persistent depression was thereby a predictor of poor 
functioning. The role of apathy was also of importance given its involvement in 
functioning, though independent of depression (Lyngstad et al., 2018).  
Another critical factor when talking about repercussions is suicide risk, which has a high 
incidence during the acute phases of psychosis, with 60% of patients reporting suicidal 
thoughts at entry. Feelings of hopelessness during FEP can increase ideation and 
attempt, thus preceding suicide (Ribeiro et al., 2018). Prodromal depression was indeed 
the main predictor of suicide which was found, implying the need for an early 
assessment (Brunett et al., 2009).  
Apart from depressive symptoms, a high risk for suicide has been associated with the 
duration of untreated psychosis, since it was during those periods that suicide rates 
were higher (Brunett et al., 2009). The contribution of insight in this depression-suicide 
tandem is uncertain, with confounding factors such as the previous history of self-harm, 
related in turn with persistent depression (Lopez-Morinigo et al., 2018).  
Limitations 
 
When considering all these findings, we must take into account the different limitations 
that could be present in each of the studies, considering the possible bias in patient 
selection, since patients presenting with symptoms in primary care are different from 
those admitted to hospitals (Dai et al., 2018); and regarding inclusion criteria, while 
some studies only included non-affective FES (Cotton et al., 2011) others were laxer 
including schizoaffective disorders (Lyngstad et al., 2018). Other variables should also be 
taken into account: time of follow-up, as symptoms of depression might be higher after 
hospital discharge or during the first time of follow-up compared to years later; 
treatment (although the definition of FEP includes patients without previous treatment, 
the treatment during the acute phase might be different between patients and we do 
not know the repercussions this could have on future measurements); and approaches 
used, with retrospective assessments presenting a higher memory bias, especially when 
it comes to the evaluation of prodromal symptoms.  
Aside from the limitations derived from each study, this review also has some of its own, 
starting from the article selection process which was carried out by a single person with 
limited knowledge into the subject and could have been susceptible to selection bias. 
Moreover, not all of the existent literature about the topic could be reviewed, perhaps 
leaving some relevant information out of this study.  
Treatment 
 
Based on all this, we can presume that it is important to assess depressive symptoms in 
FEP. Therefore, a legitimate question we can ask ourselves arises: is the use of 
antidepressants a good therapeutic option in these cases? One could think that 
depressive symptoms are produced by the same mechanisms of depression in non-
psychotic patients, hence benefiting from a similar therapeutic management.  
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The existing evidence of antidepressant therapy is derived from chronic patients, since 
not much research has been done regarding patients with a first episode. Clinical trials 
have been demonstrated successful in reducing depressive symptoms in patients with 
schizophrenia, with a higher efficacy once the psychotic phase diminishes (Gregory, 
Mallikarjun, & Upthegrove, 2017).  
Moreover, depressive symptoms in a first episode of psychosis have been consistently 
reported to have an association with the resolution of psychotic symptoms, which leads 
us to believe that there might be a common psychopathological substrate causing both 
processes. Thus, it should be imperative to understand the nature of depression in FEP 
in order to establish an effective treatment (Cotton et al., 2011). One of the possible 
tools in reducing depression at any phase of the illness is the treatment of positive 
symptoms such as paranoia or delusions, given that longer duration of untreated 
psychosis is a predictor of depression (R. J. Drake et al., 2004).  
Consequently, since most depressive symptoms are no longer present when the acute 
phase is over (Koreen AR, 1993; Oosthuizen et al., 2002), antidepressant therapy may 
be only of importance in patients with persistent depression. This would explain the 
efficacy found with the use of antidepressants in post-psychotic depression compared 
to that of an acute exacerbation (Koreen AR, 1993). As a result, treatment approaches 
for depression should be different according to the phase in which the patient is.  
In the acute phase, antipsychotic drugs seem to be the best treatment option, though it 
has also been linked to a higher severity of depression, in correlation to a better insight. 
Although initially not perfectly fitted for patients during the acute phase, 
antidepressants have been used in cases of persistent symptoms which did not respond 
adequately to neuroleptics (Oosthuizen et al., 2002). In fact, in the study by Cotton et 
al. (2011), 55.6% of patients with moderate to severe depression were prescribed 
antidepressants, with a surprisingly higher CGI-BP score at discharge compared to 
patients without antidepressants. 
The concomitant use of antidepressants and antipsychotics has been reported effective 
in reducing depression in clinical trials of patients with schizophrenia (Helfer et al., 
2016), resulting in less exacerbations (Samuel G Siris, Bermanzohn, Mason, & Shuwall, 
1994). However, it should be noted that there is a need for close monitoring when using 
both therapies simultaneously, as some antidepressants can increase antipsychotic 
medication levels (Upthegrove, 2009). Specifically, the use of fluvoxamine has been 
associated with toxic levels of clozapine (Centorrino et al., 1996).   
However, antidepressants are not normally used in FEP, with the treatment of psychotic 
symptoms playing a crucial role during the florid episode and depressive symptoms 
being negligently put aside. The study by Simonsen et al. (2018), highlights the 
requirement of a specific assessment and treatment of depressive symptoms and social 
disability in early phases of first-episode psychosis, along with the treatment of 
psychotic symptoms. As mentioned above, most depressive symptoms disappear once 
the psychosis remits, so it could be argued that there is no room for improvement with 
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the use of antidepressants during an acute phase, with psychosocial interventions 
settling as a key therapy.  
Persistent depression, on the other hand, has been associated with a shorter duration 
of treatment as well as non-compliance, which is also linked to personality disorder and 
persistent substance abuse (Cotton et al., 2011). This post-psychotic phase of the illness 
could be properly managed with the association of psychological therapies including 
psychoeducation and prevention of relapse, as well as assessing negative appraisals 
along with antidepressants if needed (Upthegrove et al., 2014).  
Furthermore, there is no widespread agreement on how to manage depression in 
schizophrenia, let alone a first episode of psychosis (Cotton et al., 2011; Gregory et al., 
2017). Apart from the above-mentioned relevance of clinical trials on establishing 
predisposing factors for depression in these patients, they are a key tool for comparing 
different treatment options, as well as observing their following repercussions. Recent 
clinical trials (table 2) are focusing on this matter. Thus, it would be interesting to know 
the results of this research in contemplation of possible future directions.  
 
 
Study NCT 
number 
Start 
date 
Completion 
date 
Status Phase Number of 
participants 
Interventions 
Cognitive Behavioral 
Therapy for Patients 
With an Early 
Psychosis 
NCT01511406 January 
2011 
October 23, 
2014 
Completed 2 60 Cognitive behavioral 
therapy 
Efficacy and Safety of 
Quetiapine in Treating 
Affective Symptoms of 
Patients With First-
episode psychosis-a 
Pilot Study 
NCT00511277 August 
2007 
April 2011 Completed 4 60 Seroquel 
Multifamily 
Psychoeducation and 
Cognitive Remediation 
for Recent-Onset 
Psychosis 
NCT01196286 June 
2010 
April 2017 Completed Not 
applicable 
40 Multifamily Group 
Psychoeducation (MFG), 
Cognitive Remediation (CR) 
Depression and 
Citalopram In First 
Episode Recovery 
(DECIFER) 
NCT01041274 January 
2010 
March 26, 
2018 
Completed 4 95 Citalopram, Placebo 
Psychoeducation, Cognitive 
Behavioral Therapy (CBT) 
Functional Magnetic 
Resonance Imaging (fMRI) 
Mediators and 
Moderators of 
Treatment Outcome in 
Recent-Onset 
Psychosis 
NCT01570972 February 
2010 
April 2017 Completed Not 
applicable 
103 Group Cognitive Behavioral 
Therapy, Multifamily Group 
Psychoeducation 
Biomarkers in First 
Episode Schizophrenia 
NCT02033382 July 2012 June 2018 Active, not 
recruiting 
 40  
Oral Versus Injectable 
Risperidone for 
Treating First-Episode 
Schizophrenia 
NCT00330551 March 
2006 
November 
2012 
Completed 4 135 Group Skills Training and 
Psychoeducation, 
Individual Case 
Management 
Oral Risperidone, 
Risperidone in Long-Acting 
Injectable Form (Consta) 
Oral Risperidone 
Versus Injectable 
Paliperidone 
Palmitate for Treating 
First-Episode 
Schizophrenia 
NCT01451736 October 
2011 
December 
2020 
Recruiting 4 170 paliperidone palmitate, 
risperidone 
Table 2: Summary of the clinical trials about treatment in First Episode Psychosis and measurements of depression. Adapted 
from hhttps://clinicaltrials.gov/ 
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Early treatment of depression in FEP would be then imperative not only for the 
improvement of symptoms but also as a main treatment goal to lower suicide risk, since 
depressive symptoms have been found associated with higher suicidality (Bornheimer, 
2018; Lopez-Morinigo et al., 2018; McGinty, Sayeed Haque, & Upthegrove, 2018). As a 
matter of fact, one of the strategies used in the prevention of suicide is antidepressant 
therapy, with secondary prevention focused on hopelessness and susceptible 
individuals and cognitive therapies conforming possible strategies for the management 
of suicide and depression. Patients with previous history of self-harm would particularly 
benefit from this, considering hopelessness as a main risk factor (Brunett et al., 2009). 
Given its repercussions in functional outcome, the treatment of these symptoms would 
be of importance preventing a worse outcome and quality of life, constituting yet 
another benefit of treating depression (Gardsjord et al., 2018).  
Until now, we have considered the different treatment possibilities for depression in 
FEP. However, as we can conclude from our review of the literature, depressive 
symptoms can appear even before the acute psychotic symptoms, which opens new 
opportunities for treatment. Can we identify susceptibility characteristics in individuals? 
Could any type of treatment or assessment of those vulnerable people, such as 
psychotherapy, offer benefits in terms of prevention or reduction of risk? These are 
some of the questions we should contemplate going forward, considering the positive 
repercussions they could have to be able to identify and treat the precursors of the 
illness or if the treatment of those precursors would even beneficial for it. Some people 
have studied high-risk groups of schizophrenia, such as Upthegrove et al. (2009), who 
evaluated the use of antidepressants in young people during their prodrome with 
successful results. Others have considered the management of these groups with the 
use of Cognitive-Behavioural Therapy (Morrison et al., 2004), even stating depression as 
the driven force of psychosis (Upthegrove, 2009). 
Finally, the management of depression in FEP could be summarized in the use of 
antipsychotic treatment during the acute phase; antidepressants if needed, with the 
knowledge derived from clinical practice and yet to be further studied; and 
psychotherapy, along with an early assessment and active tracking of risk patients. 
Moreover, treatment should be individualized since mental health disorders do not 
always follow a strict pattern but constitute a continuum with a wide variability between 
individuals. Nonetheless, more research into this subject is needed in order to have a 
full understanding of this disorder.  
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5. Conclusion 
In view of these results, we can conclude that there is a high prevalence of depression 
in people with a first episode of psychosis. Although prodromal and acute depression 
are related to post-psychotic depression, they seem to have different predisposing 
factors, which underlies the possible differences in their aetiology. The results of the on-
going or already carried out clinical trials based on FEP are of vital importance to clarify 
these unknowns. Due to the importance depression has in FEP, patients should be 
correctly assessed in terms of an early detection and proper management, with the 
knowledge derived from clinical practice and the use of different treatment strategies, 
yet to be further studied. Therefore, in order to improve patient consequences in terms 
of functioning, outcome, and suicidality, a better knowledge of depression in FEP is 
required.  
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Appendix I- Calgary Depression Scale for Schizophrenia (CDSS) 
Copyright © 2018 {Dr. D. Addington} All Rights Reserved. Interviewer:  Ask the first 
question as written. Use follow up probes or qualifiers at your discretion. Time frame 
refers to last two weeks unless stipulated. N.B. The last item, # 9, is based on 
observations of the entire interview. 
I. DEPRESSION: How would you describe your mood over the last two weeks? Do 
you keep reasonably cheerful or have you been very depressed or low spirited 
recently? In the last two weeks how often have you (own words) every day? All 
day?  
  
0. Absent  
1. Mild - Expresses some sadness or discouragement on questioning.  
2. Moderate - Distinct depressed mood persisting up to half the time over last 2 
weeks: present daily.  
3. Severe - Markedly depressed mood persisting daily over half the time 
interfering with normal motor and social functioning.  
  
II. HOPELESSNESS: How do you see the future for yourself? Can you see any future?  
Or has life seemed quite hopeless? Have you given up or does there still seem 
some reason for trying?  
  
0. Absent  
1. Mild - Has at times felt hopeless over the last two weeks but still has some 
degree of hope for the future.  
2. Moderate - Persistent, Moderate sense of hopelessness over last week. Can be 
persuaded to acknowledge possibility of things being better.  
3. Severe - Persisting and distressing sense of hopelessness.  
  
III. SELF DEPRECIATION: What is your opinion of your self compared to other 
people? Do you feel better, not as good, or about the same as other? Do you feel 
inferior or even worthless?  
  
0. Absent  
1. Mild - Some inferiority; not amounting to feeling of worthlessness.  
2. Moderate - Subject feels worthless, but less than 50% of the time.  
3. Severe - Subject feels worthless more than 50% of the time.  
May be challenged to acknowledge otherwise.  
  
IV. GUILTY IDEAS OF REFERENCE: Do you have the feeling that you are being blamed 
for something or even wrongly accused? What about? (Do not include justifiable 
blame or accusation. Exclude delusions of guilt.)  
  
0. Absent  
1. Mild - Subject feels blamed but not accused less than 50% of the time.  
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2. Moderate - Persisting sense of being blamed, and/or occasional sense of 
being accused.  
3. Severe - Persistent sense of being accused. When challenged, 
acknowledges that it is not so.  
  
V. PATHOLOGICAL GUILT: Do you tend to blame yourself for little things you may 
have done in the past? Do you think that you deserve to be so concerned about 
this?  
  
0. Absent  
1. Mild - Subject sometimes feels over guilty about some minor peccadillo, but 
less than 50% of time.  
2. Moderate - Subject usually (over 50% of time) feels guilty about past actions 
the significance of which he exaggerates.  
3. Severe - Subject usually feels s/he is to blame for everything that has gone 
wrong, even when not his/her fault.  
  
VI. MORNING DEPRESSION: When you have felt depressed over the last 2 weeks 
have you noticed the depression being worse at any particular time of day?  
  
0. Absent - No depression.  
1. Mild - Depression present but no diurnal variation.  
2. Moderate - Depression spontaneously mentioned to be worse in  
a.m.  
3. Severe - Depression markedly worse in a.m., with impaired functioning which 
improves in p.m.  
  
VII. EARLY WAKENING: Do you wake earlier in the morning than is normal for you? 
How many times a week does this happen?  
  
0. Absent - No early wakening.  
1. Mild - Occasionally wakes (up to twice weekly) 1 hour or more before normal 
time to wake or alarm time.  
2. Moderate - Often wakes early (up to 5 times weekly) 1 hour or more before 
normal time to wake or alarm.  
3. Severe - Daily wakes 1 hour or more before normal time.  
  
VIII. SUICIDE: Have you felt that life wasn’t worth living? Did you ever feel like ending 
it all? What did you think you might do? Did you actually try?  
  
0. Absent  
1. Mild - Frequent thoughts of being better off dead, or occasional thoughts of 
suicide.  
2. Moderate - Deliberately considered suicide with a plan, but made no attempt.  
3. Severe - Suicidal attempt apparently designed to end in death (i.e.: accidental 
discovery of inefficient means).  
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IX. OBSERVED DEPRESSION: Based on interviewer’s observations during the entire 
interview. The question “Do you feel like crying?” used at appropriate points in 
the interview, may elicit information useful to this observation.  
  
0. Absent  
1. Mild - Subject appears sad and mournful even during parts of the interview, 
involving affectively neutral discussion.  
2. Moderate - Subject appears sad and mournful throughout the interview, with 
gloomy monotonous voice and is tearful or close to tears at times.  
3. Severe - Subject chokes on distressing topics, frequently sighs deeply and cries 
openly, or is persistently in a state of frozen misery if examiner is sure that this 
is present. 
 
Adapted from https://www.ucalgary.ca/cdss/files/cdss/english-scale-2.-2018.pdf (Calgary, n.d.)
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Appendix 2-Clinical trials regarding First Episode of Psychosis and treatment 
Study NCT number Location Start date Completio
n date 
Status Phase Number of 
participants 
Interventions 
Efficacy and Safety of Quetiapine in 
Treating Affective Symptoms of Patients 
with First-episode psychosis-a Pilot Study 
NCT00511277 Göttingen, Germany August 2007 April 2011 Completed 4 60 Seroquel 
Clinical Trial of Integrated Treatment 
Versus Standard Treatment in First 
Episode Psychosis 
NCT00157313 Copenhagen, 
Denmark 
January 1998 December 
2022 
Active, not recruiting Not 
applicable 
600 Integrated treatment, 
family involvement, 
Social skills training 
Cognitive Behavioral Therapy for Patients 
With an Early Psychosis 
NCT01511406 Oslo, Norway January 2011 October 23, 
2014 
Completed 2 60 Cognitive behavioral 
therapy 
Integrated Metacognitive Therapy in First 
Episode Psychosis (IMT) 
NCT02131116 Indiana, United States May 2014 December 
2017 
Completed Not 
applicable 
20 Integrated 
Metacognitive Therapy, 
Treatment as Usual 
Longitudinal Long-term Study (10 Years) 
of the Sample of First Episode of Non-
affective Psychosis: PAFIP (10PAFIP) 
NCT02200588 Cantabria, Spain September 
2014 
December 
2019 
Enrolling by invitation Not 
applicable 
277  
Multifamily Psychoeducation and 
Cognitive Remediation for Recent-Onset 
Psychosis 
NCT01196286 Arizona, United States June 2010 April 2017 Completed Not 
applicable 
40 Multifamily Group 
Psychoeducation 
(MFG), Cognitive 
Remediation (CR) 
A Novel Treatment Approach for Self-
Stigma in First Episode Psychosis (BOOST) 
NCT03491852 Ontario, Canada April 1, 2018 January 
2020 
Recruiting Not 
applicable 
40 BOOST Intervention, 
Waitlist Control 
A Randomized Controlled Trial of 
Individual Therapy for First Episode 
Psychosis (PSTEP) 
NCT00722163 Ontario, Canada September 
2007 
March 2013 Unknown 1 330 Cognitive Behavioural 
Therapy, befriending 
e-Learning & Development of an 
Evidence-based Psychoeducational 
Programme for First Episode Psychosis 
NCT01783457 Barcelona/ 
Vizcaya/ Valencia/ 
Álava, Spain 
January 2011 June 2015 Completed Not 
applicable 
177 Individual 
psychoeducation 
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Graduated Recovery Intervention 
Program for Enhancing Treatment for 
First-Episode Psychosis 
NCT00307216 North Carolina, 
United States 
April 2006 December 
2008 
Completed Not 
applicable 
46 Graduated Recovery 
Intervention Program 
(GRIP), Treatment as 
usual (TAU) 
Comparative Study of Aripiprazole, 
Quetiapine and Ziprasidone in the 
Treatment of First Episode Nonaffective 
Psychosis (PAFIP2) 
NCT02305823 Cantabria, Spain October 2005 May 2014 Completed 4 203 Aripiprazole, 
Quetiapine, Ziprasidone 
Cognitive behavioural therapy program to 
First-Episode Psychosis patients and 
cannabis abuse 
NCT02319746 Alava, Spain September 
2013 
September 
2019 
Active, not recruiting Not 
applicable 
100 Cognitive-behavioral 
therapy program to 
first-episode psychosis 
patients and cannabis 
abuse, Psychoeducation 
Depression and Citalopram In First 
Episode Recovery (DECIFER) 
NCT01041274 New York, United 
States 
January 2010 March 26, 
2018 
Completed 4 95 Citalopram, Placebo 
Psychoeducation, 
Cognitive Behavioral 
Therapy (CBT) 
Functional Magnetic 
Resonance Imaging 
(fMRI) 
Cbt for Psychosis and Affect on Psychosis 
Symptoms (cbtpaps) 
NCT02653729  September 
2015 
January 
2016 
Completed 2 50 cognitive behaviour 
therapy, Espidone, 
Olepra, Donu 
Predicting Antipsychotic Discontinuation 
in Psychosis (PADP) 
NCT0288451
8 
Seoul, Republic of 
Korea 
October 4, 
2016 
December 
2018 
Active, not recruiting Not 
applicabl
e 
35 PET, clinical scale 
Anomalous Self-Experience in First 
Episode Psychosis - A Six-Year Follow-
Up Study 
NCT0232194
3 
Brumunddal, 
Norway 
February 
2015 
December 
2016 
Completed Not 
applicabl
e 
56  
Effectiveness of a Mindfulness-based 
Group Training Addressing Social 
Cognition in First Episode Psychosis 
(AGES-Mind) (AGES-Mind) 
NCT0330947
5 
Madrid, Spain September 
1, 2018 
December 
31, 2020 
Recruiting Not 
applicabl
e 
80 SocialMIND, 
Psychoeducational 
multicomponent 
intervention, 
Psychosocial 
treatment, 
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Psychotropic 
treatment 
Minnesota Community-Based 
Cognitive Training in Early Psychosis 
(Mini-COTES) 
NCT0307902
4 
Minnesota, United 
States 
May 19, 
2017 
May 19, 
2021 
Recruiting Not 
applicabl
e 
150 Targeted Cognitive 
Training, General 
Cognitive Exercises 
Psychoeducative Treatment of FEP 
With Mobile Training 
NCT0316124
9 
 February 
2019 
January 
2021 
Not yet recruiting Not 
applicabl
e 
50 Experimental group, 
Control group 
Mediators and Moderators of Treatment 
Outcome in Recent-Onset Psychosis 
NCT01570972 Arizona, United States February 
2010 
April 2017 Completed Not 
applicable 
103 Group Cognitive 
Behavioral Therapy, 
Multifamily Group 
Psychoeducation 
An Integrated Program for the Treatment 
of First Episode of Psychosis (RAISE ETP) 
NCT01321177 California/ 
Colorado/…, United 
States 
July 2010 July 2017 Completed Not 
applicable 
404 Integrated Treatment, 
Community Care 
Biomarkers in First Episode Schizophrenia NCT02033382 New York, United 
States 
July 2012 June 2018 Active, not recruiting Not 
applicable 
40  
Multi-disciplinary Treatment for Patients 
Experiencing First Episode of Psychosis 
NCT01216891 Maryland/New York, 
United States 
October 2010 August 2016 Completed Not 
applicable 
65 Multi-element, team-
oriented treatment 
Optimization of Acute Treatment in First 
Episode Schizophrenia 
NCT00157378 Munich, Germany November 
2000 
December 
2004 
Unknown 4 300 Risperidone, 
Haloperidol 
Omega-3 Fatty Acids Efficacy in First-
episode of Schizophrenia (OFFER) 
NCT02210962 Lodz, Poland September 
2011 
February 
2015 
Unknown 4 80 essential fatty acids, 
olive oil 
A Follow-Up Study of Schizophrenic 
Participants Following Treatment 
Discontinuation After Remission From a 
First Psychotic Episode 
NCT00378092 Bellville, South Africa April 2006 March 2010 Completed 4 33 Oral risperidone, 
Risperidone Long-
Acting Injection (RLAI) 
Optimizing Response in Psychosis Study 
(ORP) 
NCT00314327 New York, United 
States 
April 2006 November 
2013 
Terminated, recruitment 
was limited 
4 1 long-acting injectable 
risperidone 
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Adapted from https://clinicaltrials.gov/ (Medicine, n.d.) 
 
 
 
 
 
 
 
 
 
Oral Versus Injectable Risperidone for 
Treating First-Episode Schizophrenia 
NCT00330551 California, United 
States 
March 2006 November 
2012 
Completed 4 135 Group Skills Training 
and Psychoeducation, 
Individual Case 
Management 
Oral Risperidone, 
Risperidone in Long-
Acting Injectable Form 
(Consta) 
A Large Pragmatic Cluster Randomized 
Controlled Trial of a Multi-element 
Psychosocial Intervention for Early 
Psychosis (GETUP-PIANO) 
NCT01436331 Verona, Italy April 2010 May 2012 Completed Not 
applicable 
626 Treatment As Usual 
(TAU), TAU+CBT for 
pts+Family 
Intervention+CM. 
Oral Risperidone Versus Injectable 
Paliperidone Palmitate for Treating First-
Episode Schizophrenia 
NCT01451736 California, United 
States 
October 2011 December 
2020 
Recruiting 4 170 paliperidone palmitate, 
risperidone 
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List of Abbreviations 
AES-C: Apathy Evaluation Scale 
BAVQ-R: Beliefs about Voices Questionnaire 
CBT: Cognitive Behavioural Therapy 
CDSS: Calgary Depression Scale for Schizophrenia 
CGI-BP: Clinical Global Impressions-Severity of the Illness Scales-Bipolar Illness 
CR: Cognitive Remediation 
DOT: Details of Threat questionnaire 
DUP: Duration of untreated psychosis 
FEP: First episode of psychosis 
FES: First episode Schizophrenia 
fMRI: Functional Magnetic Resonance Imaging 
GAF-F: Global Assessment of Functioning Scale-Split version, Functioning subscale 
GRIP: Graduated Recovery Intervention Progrem 
HAMD: Hamilton Depression Rating Scale 
ICD-10: International Statistical Classification of Diseases 
IMT: Integrated Metacognitive Therapy 
IS: Insight Scale 
MDE: Major depressive episode 
MFG: Multifamily Group Psychoeducation 
ORP: Optimizing Response in Psychosis 
PANSS: Positive and Negative Symptom Scale for Schizophrenia 
PBIQ-R: Personal Beliefs about Illness Questionnaire 
PEP: Primer episodio de psicosis 
PET: Positron Emission Tomography 
PPD: Post-psychotic depression 
RLAI: Risperidone Long-Acting Injection 
SAI-E: Schedule for Assessment of Insight Scale-Expanded version 
SBQ: Safety Behaviour Questionnaire 
SCAN: Schedule for Clinical Assessment in Neuropsychiatry 
S-QoL: Subject Quality of Life 
TAU: Treatment as usual 
 
